Compare URG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URG | CTMX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.4M | 596.2M |
| IPO Year | 2006 | 2015 |
| Metric | URG | CTMX |
|---|---|---|
| Price | $1.60 | $4.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $2.46 | ★ $8.86 |
| AVG Volume (30 Days) | ★ 5.2M | 2.2M |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $27,207,000.00 | ★ $138,103,000.00 |
| Revenue This Year | $200.42 | N/A |
| Revenue Next Year | $98.46 | N/A |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | N/A | ★ 36.45 |
| 52 Week Low | $0.55 | $0.40 |
| 52 Week High | $2.35 | $6.35 |
| Indicator | URG | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 41.94 |
| Support Level | $1.47 | $4.57 |
| Resistance Level | $1.62 | $6.20 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 52.53 | 8.82 |
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.